Renaissance Technologies’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Renaissance Technologies’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,700	Closed	-$2.32M	–	4239
2023 Q2	$2.32M	Sell	10,700 -103,200	-91%	-$22.1M	﹤0.01%	1900
2023 Q1	$20.7M	Sell	113,900 -190,100	-63%	-$36.4M	0.03%	694
2022 Q4	$59.7M	Sell	304,000 -46,000	-13%	-$9.86M	0.08%	283
2022 Q3	$78.7M	Buy	350,000 +323,000	+1,196%	+$65.4M	0.11%	217
2022 Q2	$3.42M	Buy	+27,000	New	+$3.1M	﹤0.01%	1829
2022 Q1	–	Sell	-3,400	Closed	-$445K	–	4581
2021 Q4	$445K	Buy	+3,400	New	+$439K	﹤0.01%	3132
2020 Q2	–	Sell	-28,000	Closed	-$2.02M	–	3843
2020 Q1	$2.02M	Buy	+28,000	New	+$2.39M	﹤0.01%	2044

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Renaissance Technologies's KRTX Position: Q3 2023 in Review

Renaissance Technologies sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 10,700 shares — an estimated $2.32M sold.

Renaissance Technologies first reported a position in KRTX in Q1 2020 and held it in 7 quarters. The position peaked at $78.7M in Q3 2022. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

Renaissance Technologies reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Renaissance Technologies sold 10,700 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.32M.
Renaissance Technologies first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
Renaissance Technologies's Karuna Therapeutics, Inc. Common Stock position peaked at $78.7M in Q3 2022.
256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.